The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here ...

Obesity is a chronic condition and a key risk factor for a range of other health issues, including type 2 diabetes. In a ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Eli Lilly (LLY) and Company announced detailed results from the Phase 3 SURMOUNT-1 three-year study, the longest completed study to date of ...

SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...

Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. Patients on the weight-loss drug Zepbound regained weight almost one year ...